Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development

被引:263
作者
Guengerich, F. Peter [1 ,2 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA
关键词
drugs; toxicity; mechanisms; idiosyncratic responses; covalent binding; short-term assays; IN-VITRO METABOLISM; INDUCED HEPATIC NECROSIS; COVALENT BINDING DATA; HUMAN SERUM-ALBUMIN; UNITED-STATES; LIVER-INJURY; INDUCED HEPATOTOXICITY; NONHEPATOTOXIC DRUGS; URINARY BIOMARKERS; KIDNEY INJURY;
D O I
10.2133/dmpk.DMPK-10-RV-062
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Toxicity has been estimated to be responsible for the attrition of approximately one-third of drug candidates and is a major contributor to the high cost of drug development, particularly when not recognized until late in clinical trials or post-marketing. The causes of drug toxicity can be classified in several ways and include mechanism-based (on-target) toxicity, immune hypersensitivity, off-target toxicity, and bioactivation/covalent modification. In addition, idiosyncratic responses are rare but can be one of the most problematic issues; several hypotheses for these have been advanced. Although covalent binding of drugs to proteins was described almost 40 years ago, the significance to toxicity has been difficult to establish; recent literature in this field is considered. The development of more useful biomarkers and short-term assays for rapid screening of drug toxicity early in the drug discovery/development process is a major goal, and some progress has been made using "omics" approaches.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 81 条
[1]
Mechanisms of Immune-Mediated Liver Injury [J].
Adams, David H. ;
Ju, Cynthia ;
Ramaiah, Shashi K. ;
Uetrecht, Jack ;
Jaeschke, Hartmut .
TOXICOLOGICAL SCIENCES, 2010, 115 (02) :307-321
[2]
The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity [J].
Amacher, David E. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2010, 245 (01) :134-142
[3]
[Anonymous], 2004, CHALL OPP CRIT PATH
[4]
ARNOLD TH, 1983, RES COMMUN CHEM PATH, V39, P381
[6]
DRUG SAFETY DISCONTINUATIONS IN THE UNITED-KINGDOM, THE UNITED-STATES, AND SPAIN FROM 1974 THROUGH 1993 - A REGULATORY PERSPECTIVE [J].
BAKKE, OM ;
MANOCCHIA, M ;
DEABAJO, F ;
KAITIN, KI ;
LASAGNA, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :108-117
[7]
DRUG DISCONTINUATIONS IN THE UNITED-KINGDOM AND THE UNITED-STATES, 1964 TO 1983 - ISSUES OF SAFETY [J].
BAKKE, OM ;
WARDELL, WM ;
LASAGNA, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (05) :559-567
[8]
Mitochondria-targeted Cytochrome P450 2E1 Induces Oxidative Damage and Augments Alcohol-mediated Oxidative Stress [J].
Bansal, Seema ;
Liu, Chuan-Peng ;
Sepuri, Naresh B. V. ;
Anandatheerthavarada, Hindupur K. ;
Selvaraj, Venkatesh ;
Hoek, Jan ;
Milne, Ginger L. ;
Guengerich, F. Peter ;
Avadhani, Narayan G. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (32) :24609-24619
[9]
Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction [J].
Bauman, Jonathon N. ;
Kelly, Joan M. ;
Tripathy, Sakambari ;
Zhao, Sabrina X. ;
Lam, Wing W. ;
Kalgutkar, Amit S. ;
Obach, R. Scott .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :332-340
[10]
Beaune P, 1994, Adv Pharmacol, V30, P199, DOI 10.1016/S1054-3589(08)60175-1